This likely plays an important role in tumor rejection by the TGFβ signaling blockade (Gunderson et al. 2020) and may be responsible for the phenomenon of antigen spread (Gulley et al. 2017) observed in response to combinatorial treatment of 4T1 mammary carcinomas treated with galunisertib and anti-PD-L1 (Holmgaard et al. 2018). This evidence concerns the gene TGFB1 and breast carcinoma.